GEMINI-1 and -2: Rates of Confirmed Virologic Withdrawal at Wk 96 Similar With DTG Plus 3TC vs DTG Plus FTC/TDF in Treatment-Naive Patients

March 8-11, 2020; Boston, Massachusetts
Detailed analysis of confirmed virologic withdrawals shows low risk of treatment-emergent resistance in treatment-naive patients treated with DTG/3TC for initial ART.
Format: Microsoft PowerPoint (.ppt)
File Size: 163 KB
Released: March 13, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

April 2020 data from Tsepamo study on NTD prevalence following dolutegravir and other ART exposure at conception from AIDS 2020 reported by CCO

Released: July 11, 2020

Latest data from a phase I trial of capsid inhibitor lenacapavir from AIDS 2020 reported by Clinical Care Options

Released: July 10, 2020

Week 96 analysis of ADVANCE trial comparing dolutegravir + FTC/(TAF or TDF) vs EFV/FTC/TDF from AIDS 2020: Virtual, reported by CCO

Released: July 10, 2020

Download CCO slides reviewing guidelines, key studies, and individual considerations for optimizing the use of current ART regimens to treat HIV

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Babafemi Taiwo, MBBS
Released: July 6, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?